Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Syros Pharmaceuticals excels in heme programs and strategic collaborations

Syros Pharmaceuticals demonstrated strong performance in heme programs, financial resilience, and strategic collaborations, despite challenges in expenses and net losses.
The company's focus on upcoming catalysts and clinical program advancements presents opportunities for growth and innovation in the competitive biopharmaceutical landscape.
Navigating challenges in trial protocols and financial management, Syros Pharmaceuticals aims to leverage strengths in regulatory designations and partnerships for sustainable growth.

Syros Pharmaceuticals reports Q1 progress in key programs and trials

Syros Pharmaceuticals' Q1 2023 performance reflects ongoing investments in late-stage clinical programs amid revenue generation.
The company's focus on key therapeutic areas and proactive approach to trial protocols position it for potential clinical and regulatory milestones.
While facing challenges in financial performance and the need for clarity on trial-related matters, Syros Pharmaceuticals maintains a solid cash position and promising opportunities ahead.

Syros Pharmaceuticals reports Q2 progress in clinical trials and challenges

Syros Pharmaceuticals' Q2 performance reflects a focus on advancing innovative therapies for MDS and AML amid significant R&D investments.
The company faces challenges in managing financials, decision-making timelines, and balancing investments with revenue generation.
Opportunities lie in the potential of tamibarotene, strategic partnerships, and upcoming data readouts to drive future growth and value creation.

Syros Pharmaceuticals advances tamibarotene for hematologic malignancies under new CEO

Syros Pharmaceuticals is strategically advancing tamibarotene for hematologic malignancies under new leadership, with a strong financial performance in the third quarter. While facing challenges in meeting efficacy data expectations, the company has opportunities to address unmet needs in AML and MDS, positioning itself for growth.

Syros Pharmaceuticals reports positive trial results and secures $45M financing

Syros Pharmaceuticals showcased strong performance in clinical trials and financial management in Q4 2023.
While facing challenges in regulatory aspects and profitability, the company is well-positioned for growth.
Opportunities lie in upcoming trial data, product launches, and strategic initiatives for revenue expansion.
Overall, Syros Pharmaceuticals remains optimistic about its future prospects and market positioning.

Syros Pharmaceuticals advances tamibarotene with FDA Fast Track Designation

Syros Pharmaceuticals showcased progress in clinical development programs, particularly with tamibarotene, and secured FDA Fast Track Designation for AML treatment. Despite no revenue in Q1 2024, the company's financial position remains stable with $108.3 million in cash and extended financial flexibility. Challenges include revenue impact from terminated agreements and the need to navigate market competition.

Syros Pharmaceuticals reports Q2 loss, eyes market expansion opportunities

Syros Pharmaceuticals showcased progress on tamibarotene trials with positive results in MDS and AML.
Financial performance in Q2 2024 reflected a net loss but maintained solid cash reserves for operations.
Analyst inquiries and executive insights highlighted strategic focus on pivotal studies and commercialization plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Syros Pharmaceuticals Inc. Investors Are Urged To Partake In An Inquiry Into Possible Securities Law Violations With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.

ATTENTION Syros Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.

Levi & Korsinsky Reminds Shareholders of an Investigation into Syros Pharmaceuticals, Inc. (SYRS) Regarding Potential Securities Fraud Allegations

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders With Losses In Syros Pharmaceuticals, Inc. Are Invited To Participate In A Securities Fraud Investigation With The Schall Law Firm

Syros Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SYRS

Lost Money on Syros Pharmaceuticals, Inc.(SYRS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

LOS ANGELES--(BUSINESS WIRE)--SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm.

SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.

SYRS ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Syros Pharmaceuticals, Inc.

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.

Syros Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SYRS

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.

Investors who lost money on Syros Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - SYRS

Syros Pharmaceuticals, Inc. (SYRS) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

An Investigation Has Commenced on Behalf of Syros Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SYRS Losses.

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros Pharmaceuticals (SYRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Syros Pharmaceuticals (NASDAQ: SYRS ) stock is falling hard on Tuesday after the biopharmaceutical company provided an update on a Phase 2 clinical trial. Syros Pharmaceuticals has announced that it is discontinuing enrollment in its SELECT-AML-1 Phase 2 clinical trial.

Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute.

Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

The average of price targets set by Wall Street analysts indicates a potential upside of 251.9% in Syros Pharmaceuticals (SYRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q2 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications Conley Chee - President and Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Ted Tenthoff - Piper Sandler Roy Buchanan - Citizens JMP Leah Cann - Brookline Capital Markets Operator Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Syros Pharmaceuticals, Inc. (SYRS) Q2 2024 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update. “Syros is well-positioned heading into key clinical data readouts expected in the second half of 2024, including pivotal complete response (CR) data from the Phase 3 SELECT-MDS-1 trial by mid-fo.

Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its second quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (internat.

Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.

Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why

Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing.

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tues.

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Karen Hunady - Director of IR and Corporate Communications Conley Chee - CEO David Roth - CMO Jason Haas - CFO Conference Call Participants Phil Nadeau - TD Cowen Operator Good morning and welcome to Syros Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update. “In 2024, we are acutely focused on execution across clinical and pre-commercial activities as we advance tamibarotene toward critical milestones, including additional data from the Phase 2 SEL.

News for Syros Pharmaceuticals Stock (SYRS)